Dysmenorrhea

(redirected from dysmenorrheal)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

dysmenorrhea

[dis‚men·ə′rē·ə]
(medicine)
Difficult or painful menstruation.

Dysmenorrhea

 

disturbances of menstruation, characterized by pains in the lower abdomen, the small of the back, and the sacrum (algomenorrhea), combined with general symptoms (migraine, heart palpitations, vomiting, diarrhea, skin rashes, and sleep disturbance).

Primary dysmenorrhea occurs in women with no previous gynecological disease, most often in young girls and young women who have not given birth. This dysmenorrhea often ceases with a regular sex life and especially after parturition. Secondary dysmenorrhea appears as a result of inflammatory processes, the development of tumors in the woman’s sex organs, version of the uterus, and so on. Dysmenorrhea may develop as a result of psychological shock associated with the onset of the first menstruation in uninformed young girls, when there is a long-unfulfilled desire to become pregnant, and in cases of unsatisfactory sex life. Sometimes dysmenorrhea arises owing to the functional characteristics of a woman’s nervous system (vagotonic form). A special form of dysmenorrhea is membranous dysmenorrhea, which is associated with hormonal disharmony (the preponderance of estrogen over the hormone of the corpus luteum).

Treatment depends on the causes of the dysmenorrhea and its form. General restorative treatment, pain relievers, sedatives, hormone therapy, and physical therapy are prescribed.

References in periodicals archive ?
Analgesia with ibuprofen arginate versus conventional ibuprofen for patints with dysmenorrheal.
Bextra, originally approved to treat rheumatoid arthritis, osteoarthritis and primary dysmenorrheal in women, helped increase sales for Pfizer to $139 million in the third quarter of 2002 with its off-label promotions, the suit claimed.
A comparative study of theeffect of high-intensity transcutaneous nerve stimulation and oral naproxen on intrauterine pressure and menstrual pain in patient with primary dysmenorrheal.
Bextra, originally approved to treat rheumatoid arthritis, osteoarthritis and primary dysmenorrheal in women, helped increase Pfizer sales to $139 million in the third quarter of 2002 with its off-label promotions, the suit claimed.